Analysis-AstraZeneca's US listing may pull other firms from London in its wake

Analysis-AstraZeneca’s US listing may pull other firms from London in its wake

By Charlie Conchie LONDON (Reuters) -AstraZeneca’s move to upgrade its listing in the U.S. risks pulling liquidity away from London’s stock market and could pave the way for other large companies to follow suit, analysts, investors and advisers said. The British drugmaker, one of London’s most valuable listed companies, said on Monday it would retain…

Read More
Markets are selling off after Powell said six words investors don’t want to hear: ‘Equity prices are

Markets are selling off after Powell said six words investors don’t want to hear: ‘Equity prices are

Markets fell after Fed Chairman Jerome Powell warned that stocks are “highly valued.” U.S. stocks dropped, with tech leading losses on skepticism over Nvidia’s $100 billion OpenAI deal. Europe and U.K. markets opened lower. U.S. Federal Reserve Chairman Jerome Powell gave a speech in Rhode Island yesterday and, afterwards, was asked whether the Fed was…

Read More